We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Axonics Inc | NASDAQ:AXNX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.15 | 0.22% | 67.72 | 66.87 | 68.95 | 67.79 | 67.54 | 67.70 | 230,082 | 01:00:00 |
From Dec 2023 to Jun 2024
By Ben Glickman
Boston Scientific will acquire Axonics for about $3.7 billion in cash.
The companies said on Monday that Axonics had agreed to be bought for $71 a share. Boston Scientific said the deal gave Axonics an equity value of $3.7 billion and an enterprise value of $3.4 billion.
Axonics is developing medical technology focused on treating urinary and bowel issues.
Boston Scientific said the deal would add technologies to its portfolio to further serve urologists.
The deal is expected to close in the first half of 2024, subject to the approval of Axonics stockholders and the receipt of regulatory approvals.
Axonics will become a wholly-owned subsidiary of Boston Scientific.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 08, 2024 07:26 ET (12:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Axonics Chart |
1 Month Axonics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
